<DOC>
	<DOCNO>NCT02347332</DOCNO>
	<brief_summary>For patient relapse platinum-based therapy , data available . The current use cetuximab associate radiotherapy localize disease associate platinum-based chemotherapy first-line setting stress need new therapeutic option later stage SCCHN.Vinca-alkaloids demonstrate activity SCCHN . Vinflunine demonstrate superior antitumour activity vinorelbine preclinical animal model . Recent preliminary phase I result vinflunine plus methotrexate combination SCCHN , base clinical review , show encouraging antitumour activity acceptable safety profile . Therefore combination vinflunine methotrexate appear promising salvage regimen platinum failure . The present study design multicenter , randomise phase III study compare combination IV vinflunine methotrexate methotrexate alone SCCHN patient fail platinum-based therapy .</brief_summary>
	<brief_title>Phase III Study Vinflunine Plus Methotrexate Versus Methotrexate Alone Patients With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm recurrent and/or metastatic squamous cell carcinoma Documented progressive disease chemotherapy locoregionally advance recurrent/metastatic SCCHN include platinum derivative Measurable non measurable disease adequate haematological , hepatic renal function WHO performance status &lt; 1 Nasopharyngeal carcinoma History brain leptomeningeal involvement Albumin level &lt; 35 g/L Patients weight loss â‰¥ 5 % within last 3 month Grade &gt; 2 peripheral neuropathy study entry `` Third space '' fluid ( pleural effusion , ascites , massive edema ) Prior treatment vincaalkaloids methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>